Clinical Trial Update: AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 2 open-label long-term extension study of bapineuzumab in patients with mild to moderate Alzheimer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AAB-001 (Bapineuzumab) (bapineuzumab)

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED